FIELD: medicine. SUBSTANCE: method involves determining concentration of estrogen and/or progesterone receptors in tumor tissue. The level being high, trial endocrine therapy is administered for 1-4 months with dynamic evaluation of tumor size being done. Objectively positive answer being obtained, the patients are subjected to surgical intervention with adjuvant endocrine therapy administered in the following period applying the preparation proved to be the most effective at the trial therapy stage. EFFECT: increased general and recidivation-free survival period.
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR COMPLEX EVALUATION OF TUMOR SENSITIVITY TO CHEMOTHERAPY AT MAMMARY GLAND CANCER | 2001 |
|
RU2220418C2 |
| METHOD FOR PREDICTION OF ANTI-OESTROGEN TAMOXIFEN THERAPY EFFECTIVENESS IN PATIENTS WITH LUMINAL BREAST CANCER | 2014 |
|
RU2558857C1 |
| METHOD FOR PREDICTION OF HORMONE DEPENDENCE OF BREAST CANCER IN PRIMARY MENOPAUSAL PATIENTS | 2014 |
|
RU2562538C2 |
| METHOD FOR ESTIMATING TUMOR HORMONE DEPENDENCE OF LOW-DIFFERENTIATED ENDOMETRIUM CARCINOMA AND ITS SENSITIVITY TO AROMATASE INHIBITORS | 2006 |
|
RU2317555C2 |
| DOSIMETRIC METHOD FOR PLANNING INTRATISSULAR BRACHITHERAPY WITH ORGAN-SAVING TREATING OF MAMMARY GLAND CANCER | 2000 |
|
RU2174019C1 |
| METHOD FOR PREDICTION OF FULL REGRESSION PROBABILITY DURING NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH THREE-TIMES NEGATIVE MOLECULAR-GENETIC SUBTYPE OF BREAST CANCER | 2016 |
|
RU2623118C1 |
| METHOD FOR DETECTING LATENT ESTROGENOSENSITIVITY IN CASE OF RECEPTOR-NEGATIVE CANCER OF UTERINE BODY | 2003 |
|
RU2265220C2 |
| METHOD FOR PREDICTING THE COURSE OF A PATHOLOGICAL PROCESS IN LUMINAL NON-HYPEREXPRESSION OF Her2Neu PRIMARY OPERABLE BREAST CANCER IN POSTMENOPAUSAL WOMEN | 2018 |
|
RU2694843C1 |
| METHOD FOR COMPLEX TREATMENT OF RESECTABLE FORMS OF ENDOMETRIAL CANCER | 2005 |
|
RU2297798C1 |
| METHOD FOR DETECTING DNA-DAMAGING CAPACITY OF ESTROGENS | 2001 |
|
RU2223503C2 |
